New Delhi, India is set to emerge as a global leader in the homoeopathy sector, driven by strong clinical expertise, large-scale practitioner networks, and internationally recognised quality certifications and standards.
India has over 2.5 lakh registered homoeopathy practitioners, nearly 300 teaching institutions, and millions of patients relying on homoeopathy as their primary or complementary system of medicine.
The global homoeopathy market is valued at over USD 8 to 10 billion, with Europe accounting for a significant share, historically dominated by Germany.
Experts believe that quality-backed Indian brands are now well-positioned to challenge this dominance, citing the AYUSH Premium Mark and NABL accreditation as key differentiators.
Dr Pradeep Prajapati, Director of the All India Institute of Ayurveda, said, 'The key differentiator lies in certified quality and scientific validation.'
Rajeshwar Tiwari, a senior representative from the Ministry of AYUSH, added, 'When this experiential advantage is supported by certified quality frameworks like AYUSH Premium and NABL, Indian homoeopathy gains scientific credibility that is globally comparable.'
Adven Biotech has become India's first homoeopathy company to receive both the AYUSH Premium Mark and NABL certification, with CEO Adesh Sharma saying, 'AYUSH Premium and NABL are not just certificates; they are global passports for Indian homoeopathy.'
Experts estimate that Indian homoeopathy exports could grow two to three times in the next five to seven years, especially in regulated markets.
